Financhill
Sell
30

QURE Quote, Financials, Valuation and Earnings

Last price:
$21.33
Seasonality move :
13.74%
Day range:
$20.55 - $22.98
52-week range:
$6.62 - $71.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
72.88x
P/B ratio:
5.81x
Volume:
3.5M
Avg. volume:
4M
1-year change:
223.67%
Market cap:
$1.3B
Revenue:
$27.1M
EPS (TTM):
-$4.39

Earnings Data

Next earnings date for QURE
Feb 26
2026
Most recent earnings per share
-$1.38
Missed by $0.52
(Nov 10/2025)
Consensus Estimate
-$0.86
(Nov 10/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

QURE Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
02/26/2026 Q4 $5.8M -- -- -$0.93 --
11/10/2025 Q3 $5.2M $3.7M -$1.38 -$0.86 -$0.52
07/29/2025 Q2 $5.8M $5.3M -$0.69 -$0.88 $0.19
05/06/2025 Q1 $6.7M $1.6M -$0.82 -$1.06 $0.24
02/27/2025 Q4 $19.4M $5.2M -$1.50 -$0.54 -$0.96
11/05/2024 Q3 $7.1M $2.3M -$0.91 -$1.01 $0.10
08/01/2024 Q2 $6.8M $11.1M -$1.16 -$1.25 $0.09
05/07/2024 Q1 $6.3M $8.5M -$1.36 -$1.26 -$0.10
02/28/2024 Q4 $6.1M $6.7M -$1.53 -$1.39 -$0.14
11/07/2023 Q3 $4.6M $1.4M -$1.88 -$0.77 -$1.11
08/01/2023 Q2 -- $2.4M -$1.44 -- --
05/09/2023 Q1 -- $5.3M -$1.63 -- --
02/27/2023 Q4 -- $102.7M $0.14 -- --
11/02/2022 Q3 -- $1.4M -$1.02 -- --
08/08/2022 Q2 -- $497K -$0.84 -- --
05/02/2022 Q1 -- $1.8M -$1.00 -- --
03/01/2022 Q4 -- $57.7M $0.17 -- --
10/25/2021 Q3 -- $2M -$0.79 -- --
07/26/2021 Q2 -- $463.9M $8.51 -- --
05/10/2021 Q1 -- $454K -$0.91 -- --
03/01/2021 Q4 -- $34.1M -$0.02 -- --
10/27/2020 Q3 -- $1.8M -$1.21 -- --
07/30/2020 Q2 -- $1.5M -$0.96 -- --
04/29/2020 Q1 -- $104K -$0.63 -- --
03/02/2020 Q4 -- $2.6M -$0.95 -- --
10/28/2019 Q3 -- $1M -$0.58 -- --
07/29/2019 Q2 -- $2.5M -$0.83 -- --
04/29/2019 Q1 -- $1.1M -$0.74 -- --
02/28/2019 Q4 -- $1.6M -$0.59 -- --
11/06/2018 Q3 -- $3.1M -$0.59 -- --
08/08/2018 Q2 -- $3.1M -$0.57 -- --
04/30/2018 Q1 -- $3.5M -$0.59 -- --
12/31/2017 Q4 -- $2.6M -$0.89 -- --
11/01/2017 Q3 -- $2.3M -$0.40 -- --
08/08/2017 Q2 -- $4.9M -$0.83 -- --
03/31/2017 Q1 -- $3.3M -$0.80 -- --
04/03/2017 Q4 -- -- -- -- --
11/22/2016 Q3 -- $7.2M -$0.61 -- --
08/25/2016 Q2 -- $4.5M -$0.87 -- --
06/09/2016 Q1 -- $4.7M -$0.99 -- --
04/04/2016 Q4 -- $3.9M -$0.64 -- --

uniQure NV Earnings Questions

  • How Much did uniQure NV Generate in Revenue Last Quarter?

    uniQure NV reported $3.7M worth of top line sales in its most recent quarter.

  • Did uniQure NV Beat Earnings Last Quarter?

    uniQure NV announced earnings per share of -$1.38 which represents a miss of analyst forecast a -$0.86 per share.

  • Is uniQure NV Profitable?

    uniQure NV reported -$329K that represents -$0.01 per share over the last quarter.

  • What is the Analyst Consensus for uniQure NV EPS Next Year?

    uniQure NV's earnings are forecast to decrease from -$4.92 per share to -$3.90 per share next year representing a decrease of -22.17%.

  • When is uniQure NV's Earnings Date?

    uniQure NV's next earnings date is February 26, 2026.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Robinhood Win AI Investing?
Will Robinhood Win AI Investing?

Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 62x

Buy
56
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 37x

Buy
81
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Buy
56
SMX alert for Dec 6

SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.

Buy
62
PRAX alert for Dec 6

Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.

Sell
13
PSN alert for Dec 6

Parsons Corp. [PSN] is down 21.1% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock